BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Treatment
492 results:

  • 1. Dosimetric Comparison of Isodose Surface Volume and Total Reference Air Kerma (TRAK) based Volume in Cervical cancer Brachytherapy.
    Thimmaiah N; Malavade V; A S UK; S S; Pasha C R T; Vishwanath L
    Asian Pac J Cancer Prev; 2024 Feb; 25(2):587-594. PubMed ID: 38415545
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Redefining the role of pulsed-dose-rate brachytherapy in cervical cancer treatment using a preplanned approach.
    Annede P; Robert C; Espenel S; Dumas I; Chargari C
    Brachytherapy; 2024; 23(2):107-114. PubMed ID: 38105154
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Simultaneous catheter and multicriteria optimization for hdr cervical cancer brachytherapy with a complex intracavity/interstitial applicator.
    Bélanger C; Aubin S; Lavallée MC; Beaulieu L
    Med Phys; 2024 Mar; 51(3):2128-2143. PubMed ID: 38043067
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Image-guided high-dose-rate brachytherapy as the method of choice in medically inoperable early-stage endometrial cancer patients.
    Rydzinski M; Bijok M; Michalski W; Kowalczyk A; Gruszczynska E; Zolciak-Siwinska A
    Gynecol Oncol; 2024 Jan; 180():6-13. PubMed ID: 38035868
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Efficacy of high-dose-rate brachytherapy with different radiation source activities among cervical cancer patients and risk factors for long-term outcomes: A 6-year retrospective study.
    Wen F; Li C; Liang B; You J; Li X; Wang J; Liu H; Wang F; Dong Z; Zhang Y
    Brachytherapy; 2024; 23(1):35-44. PubMed ID: 37919124
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. External Beam Radiotherapy Interdigitated with High Dose Rate(hdr) Intracavitary Brachytherapy versus External Beam Radiotherapy followed by Sequential hdr Intracavitary Brachytherapy for Locally Advanced Carcinoma Cervix-Randomized Control Study.
    Gupta IJ; Ghosh A; Yadav J; Tuteja JS; Gupta R; Srivastava K; Verma M; Gupta S; Srivastava S; Bhatt MLB
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3441-3445. PubMed ID: 37898849
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Interfraction variations in doses at OARs during three-dimensional high dose rate brachytherapy planning of cervix cancer.
    Dhaka S; Rajani A; Kumar HS; Sharma N; Jakhar SL; Harsh K
    J Cancer Res Ther; 2023; 19(5):1136-1141. PubMed ID: 37787275
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle-income countries.
    Grover S; Lichter KE; Likhacheva A; Jang JW; Ning MS; Robin TP; Small W; Kudchadker RJ; Swamidas J; Chopra S; Rai B; Sharma SD; Sharma DN; Kuppusamy T; Yang R; Berger D; Mendez LC; Glaser S; Erickson DL; Chino J; Mourtada F; Abdel-Wahab M; Jhingran A; Simonds H; Mahantshetty U
    Brachytherapy; 2023; 22(6):716-727. PubMed ID: 37704540
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The population percentile allowance method for determining systematic spatial error tolerances for temporary intensity modulated brachytherapy.
    Hopfensperger KM; Adams QE; Kim Y; Wu X; Xu W; Patwardhan K; Flynn RT
    Med Phys; 2023 Oct; 50(10):6469-6478. PubMed ID: 37643427
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Brachytherapy for targeting the immune system in cervical cancer patients.
    Linares I; Berenguer Frances MÁ; Cañas R; Najjari D; Gutiérrez C; Marín S; Comas S; Guedea F; Pujol M
    BMC Immunol; 2023 Aug; 24(1):23. PubMed ID: 37559025
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A linear optimization model for high dose rate brachytherapy using a novel distance metric.
    Mirzavand Boroujeni N; Richard JP; Sterling D; Wilke C
    Phys Med Biol; 2023 Aug; 68(17):. PubMed ID: 37489861
    [No Abstract]    [Full Text] [Related]  

  • 12. Ovarian Mesonephric-Like Adenocarcinoma With Recurrent Liver Metastases: A Case Report with Analysis of Therapeutic Molecular Targets.
    Sugitani A; Ogawa A; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
    Int J Surg Pathol; 2024 May; 32(3):578-585. PubMed ID: 37345348
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Partial-Length treatment With Brachytherapy in Patients With Endometrial cancer With High-Risk Features Is as Effective as Full-Length Vaginal Brachytherapy but With Reduced Toxicity.
    Wernicke AG; Parashar B; Samuel E; Sabbas A; Gupta D; Caputo T
    Pract Radiat Oncol; 2023; 13(5):e416-e422. PubMed ID: 37295725
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Dose and secondary cancer-risk estimation of patients undergoing high dose rate intracavitary gynaecological brachytherapy.
    Doudoo CO; Gyekye PK; Emi-Reynolds G; Adu S; Kpeglo DO; Nii Adu Tagoe S; Agyiri K
    J Med Imaging Radiat Sci; 2023 Jun; 54(2):335-342. PubMed ID: 37087327
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Self-configuring nnU-Net for automatic delineation of the organs at risk and target in high-dose rate cervical brachytherapy, a low/middle-income country's experience.
    Duprez D; Trauernicht C; Simonds H; Williams O
    J Appl Clin Med Phys; 2023 Aug; 24(8):e13988. PubMed ID: 37042449
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. In-vivo Comparison of Planned and Measured Rectal Doses during Cobalt-60 hdr CT-based Intracavitary Brachytherapy Applications of Cervical cancer Using the PTW 9112 Semiconductor Probe.
    Johan SK; Lobo D; Athiyamaan MS; Srinivas C; Banerjee S; Abhishek K; Saxena PUP
    Asian Pac J Cancer Prev; 2023 Mar; 24(3):897-907. PubMed ID: 36974543
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Metastasis of endometrial cancer to breast: A rare case.
    Erdoğan Ö; Balci MF; Özgüzer A; Özdaş E; Görgülü G; Sanci M
    J Obstet Gynaecol Res; 2023 May; 49(5):1452-1455. PubMed ID: 36828642
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Communicating the Gynecologic Brachytherapy Experience (CoGBE): Clinician perceived benefits of a graphic narrative discussion guide.
    Avila S; Ruiz MJ; Petereit D; Arya R; Callender B; Hasan Y; Kim J; Lee N; McCall A; Son C; Stack K; Asif S; Besecker T; Juneja A; Li Z; Naik P; Ranka T; Saxena P; Siegfried B; Ichikawa T; Golden DW
    Brachytherapy; 2023; 22(3):352-360. PubMed ID: 36681540
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Epithelioid trophoblastic tumor: A case series.
    Dash SS; Sakhadeo U; Karmarkar S; Mittal N; Menon S; Rekhi B; Deodhar KK
    Indian J Pathol Microbiol; 2023; 66(1):148-151. PubMed ID: 36656227
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer.
    Williamson CW; Kotha NV; Zou J; Brown D; Scanderbeg D; Rash D; Einck J; Yashar C; Mell LK; Mayadev J
    Brachytherapy; 2023; 22(3):317-324. PubMed ID: 36631374
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 25.